Age-specific population centiles for androgen status in men
Age-specific population centiles for androgen status in men
复制标题
DOI：
10.1530/eje-15-0380
复制
发表时间：
2015-12-01
影响因子：
5.8
通讯作者：
Ly, Lam P.
中科院分区：
文献类型：
--
作者：
Handelsman, D. J.;Yeap, B. B.;Ly, Lam P.
目的：男性在整个成年期内循环睾酮及其两种生物活性代谢物双氢睾酮（DHT）和雌二醇（E-2）的年龄特异性人群特征及其决定因素尚未得到很好的描述。目的：我们的目标是推导出循环睾酮，DHT，和E-2在男性中使用来自澳大利亚三个城市的基于人群的研究的汇总数据，来自单个实验室的液相色谱-质谱类固醇测量。设计，设置，和与会者：我们汇总了10904份血清样本的数据（血清睾酮、双氢睾酮、E-2、年龄、身高和体重）。主要结果测量：通过大样本数据分析方法推导出35-100岁男性血清睾酮、双氢睾酮和E-2的特定平滑百分位数。我们发现，血清睾酮，双氢睾酮，和E-2从35岁开始逐渐下降，80岁后下降更明显。较高的体重、BMI、体表面积以及较矮的身材与血清睾酮、双氢睾酮和E-2的降低相关。结论：在澳大利亚男性中，在男性老龄化过程中，雄激素状态呈逐渐进行性的全人群下降，直到80岁，之后有更明显的下降。肥胖和身材矮小与雄激素水平降低有关。对年龄相关性雄激素状态下降的研究应关注年龄相关性合并症的进行性累积，以更好地为最佳临床试验设计提供信息。
Aim: The age-specific population profiles in men of circulating testosterone and its two bioactive metabolites dihydrotestosterone (DHT) and estradiol (E-2) across the adult lifespan and its determinants are not well described.Objective: Our objective was to deduce smoothed age-specific centiles of circulating testosterone, DHT, and E-2 in men using pooled data from population-based studies in three Australian cities from liquid chromatography-mass spectrometry steroid measurements in a single laboratory.Design, setting, and participants: We pooled data of 10 904 serum samples (serum testosterone, DHT, E-2, age, height, and weight) from observational population-based studies in three major cities across Australia.Main outcome measures: Age-specific smoothed centiles for serum testosterone, DHT, and E-2 in men aged 35-100 years were deduced by large sample data analysis methods.Results: We found that serum testosterone, DHT, and E-2 decline gradually from ages 35 onwards with a more marked decline after 80 years of age. Higher weight, BMI, and body surface area as well as shorter stature are associated with reduced serum testosterone, DHT, and E-2.Conclusions: Among Australian men, there is a gradual progressive population-wide decline in androgen status during male aging until the age of 80 years after which there is a more marked decline. Obesity and short stature are associated with reduced androgen status. Research into the age-related decline in androgen status should focus on the progressive accumulation of age-related comorbidities to better inform optimal clinical trial design.